Availability of the Q3 2022 memorandum for modeling purposes
Paris, France – September 28, 2022 – Sanofi announced today that its Q3 2022 memorandum is available for modeling purposes on the Investors page of the company’s website:
https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2022
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group’s quarterly results. This document contains a reminder of various non-comparable items and exclusivity losses as well as the impact of foreign currency and the number of shares. Sanofi’s third quarter 2022 results will be released on October 28, 2022.
Around Sanofi
We are an innovative global healthcare company driven by one purpose: we hunt the wonders of science to improve people’s lives. Located in approximately 100 countries, our team is dedicated to transforming medical practice by working to make the impossible possible. We bring potentially life-changing treatments and life-saving immunizations to millions of people around the world, while putting sustainability and social responsibility at the heart of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Gundoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com
Nicholas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
Investor Relations
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix eavesdropper | + 1 908 612 7239 | felix.lauscher@sanofi.com
priya Nanduri | + 1 617 764 6418 | priya.nanduri@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Sanofi Forward-Looking Statements
This press release contains…
